{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-24-000031","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2024-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.486757+00:00","generated_at":"2026-06-03T06:15:38.149201+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Halozyme stockholders elect directors, approve executive compensation and charter amendment at 2024 annual meeting","bullets":["Barbara Duncan elected with 90.1M votes for, Mahesh Krishnan with 104.0M votes for, each to three-year term.","Advisory vote on named executive officer compensation passed 102.9M for vs 2.2M against.","Amendment to certificate of incorporation to exculpate officers approved 91.5M for vs 13.6M against; filed with Delaware on April 25.","Ratification of Ernst & Young as auditor for FY2024 passed 114.9M for vs 0.6M against."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-24-000031","json":"https://secwatch.observer/filing/0001159036-24-000031.json","markdown":"https://secwatch.observer/filing/0001159036-24-000031.md","text":"https://secwatch.observer/filing/0001159036-24-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000031/0001159036-24-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000031/halo-20240425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T06:15:38.149201+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"87f33d4cfbc5175dfe842a6c208da2b76e9e6e18","claim":"HALOZYME THERAPEUTICS, INC. shareholders approved Election of two Class II directors to hold office for a three-year term expiring at the 2027 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified at the 2024-04-25 meeting.","evidence_excerpt":"Proposal 1 : Election of two Class II directors to hold office for a three-year term expiring at the 2027 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified: Names Votes For Votes Against Abstain Broker Non-Votes Barbara Duncan 90,120,424 15,016,536 161,704 10,383,116 Mahesh Krishnan, M.D. 103,968,663 1,164,017 165,984 10,383,116 Each of the foregoing candidates was elected and each received affirmative votes from more than a majority of the outstanding shares.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000031/0001159036-24-000031-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-25"}],"fact_type":"shareholder_vote"},{"claim_id":"b32b7570c1ee55f7316203f5c8262038b56f66e9","claim":"HALOZYME THERAPEUTICS, INC. shareholders approved The advisory vote on the compensation of the Company’s named executive officers at the 2024-04-25 meeting.","evidence_excerpt":"Proposal 2 : The advisory vote on the compensation of the Company’s named executive officers was as follows: Votes For Votes Against Abstain Broker Non-Votes 102,860,435 2,190,603 247,626 10,383,116 The foregoing proposal was approved.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000031/0001159036-24-000031-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-25"}],"fact_type":"shareholder_vote"},{"claim_id":"bdeb9179ff0be060d7310c435dbdd87c80c78ce6","claim":"HALOZYME THERAPEUTICS, INC. shareholders approved Approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers at the 2024-04-25 meeting.","evidence_excerpt":"Proposal 3: The vote on a proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding exculpation of officers was as follows: Votes For Votes Against Abstain Broker Non-Votes 91,512,252 13,612,616 173,796 10,383,116 The foregoing proposal was approved.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000031/0001159036-24-000031-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-25"}],"fact_type":"shareholder_vote"},{"claim_id":"f1d205e32510eb87d7e5d9d20f446816b429e734","claim":"HALOZYME THERAPEUTICS, INC. shareholders approved Ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-04-25 meeting.","evidence_excerpt":"Proposal 4 : The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was as follows: Votes For Votes Against Abstain Broker Non-Votes 114,912,469 647,868 121,443 — The foregoing proposal was approved.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000031/0001159036-24-000031-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-04-25"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}